The transcription factor NF-κB (nuclear factor kappa enhancer binding protein) controls many processes, including immunity, inflammation and apoptosis. Ubiquitination regulates at least three steps in the NF-κB pathway: degradation of IκB (inhibitor of NF-κB), processing of NF-κB precursors, and activation of the IκB kinase (IKK). Recent studies have revealed several enzymes involved in the ubiquitination and deubiquitination of signalling proteins that mediate IKK activation through a degradationindependent mechanism.
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In this post-genomic era, filled with cutting-edge technologies, it is refreshing to look back at the history of ubiquitin and NF-κΒ, as both were discovered through an ingenious combination of simple 'bucket' biochemistry and a clear mind [1] [2] [3] [4] [5] . Since these classic experiments were done, both ubiquitin and NF-κB have taken centre stage in biology, as each controls a vast array of cellular and organismal processes, ranging from the birth and death of a cell to the neuronal behaviour of an organism. Again, it was through biochemistry that the essential role of ubiquitination in NF-κΒ activation was revealed [6] [7] [8] . Ubiquitin targets not only IκΒ for degradation, but also the NF-κΒ precursors, p105 and p100, for processing into mature forms by the proteasome. More surprisingly, a key role for ubiquitination in activating protein kinases in the NF-κΒ pathway through a degradation-independent mechanism has also been discovered [9] [10] [11] . Therefore, the convergence of ubiquitin and NF-κΒ research has not only helped to elucidate the biochemical mechanisms underlying NF-κB activation, but has also broadened our understanding of ubiquitin as a versatile signalling tag. As several extensive reviews of ubiquitination in the NF-κB pathway are available 12, 13 , here I will summarize the current view of the traditional role of ubiquitin in the NF-κΒ pathway, and then focus on recent advances in understanding the non-traditional role of ubiquitin in this pathway.
The traditional role of ubiquitin in the NF-κΒ pathway NF-κΒ is a dimeric transcription factor that consists of REL family members, including REL-A (also known as p65), c-REL, REL-B, p50 and p52 (ref. 14) . p50 and p52 are derived from the larger precursors p105 and p100, respectively, through proteolytic processing by the proteasome. All NF-κΒ proteins contain a highly conserved REL-homology domain (RHD) that is responsible for DNA binding, dimerization, nuclear translocation and interaction with the IκΒ proteins. The IκΒ proteins, including IκΒα, β and ε, bind to NF-κΒ via ankyrin repeats and block its nuclear import and, thereby, its transcriptional activity. The carboxyl termini of p105 and p100 also contain the IκB-like ankyrin repeats that must be degraded to generate the mature REL subunits.
The NF-κΒ activation pathways are broadly classified as either the canonical or the non-canonical pathway. This classification depends on whether activation involves IκΒ degradation or p100 processing (Fig. 1) 15 . In the canonical pathway, which is the predominant NF-κΒ signalling pathway, stimulating cells with an agonist such as tumour necrosis factor-α (TNFα) or interleukin-1β (IL-1β) activates the IKK complex, which is composed of two catalytic subunits, IKKα and IKΚβ, and a regulatory subunit, NEMO (also known as IKKγ). Genetic experiments have demonstrated that IKΚβ, but not IKKα, phosphorylates IκΒ proteins at two amino-terminal serine residues in vivo. This signal-induced phosphorylation targets IκΒ for polyubiquitination and subsequent degradation by the proteasome 7 , thereby releasing NF-κΒ. The non-canonical pathway of NF-κΒ activation operates mainly in B cells in response to stimulation of a subset of the TNF-receptor (TNFR) superfamily, including receptors for BAFF, lymphotoxin-β (LTβ) and CD40 ligand. Stimulation of these receptors activates the protein kinase NIK, which in turn activates IKKα. IKKα then phosphorylates p100 at two C-terminal serine residues, leading to the selective degradation of its IκΒ-like domain by the proteasome 16, 17 . The mature p52 subunit and its binding partner, REL-B, translocate into the nucleus to regulate gene expression.
The ubiquitin-proteasome pathway plays a crucial role in both the canonical and non-canonical pathways of NF-κB activation. Ubiquitination is a reversible covalent modification that is catalysed by three enzymatic steps 18 . In the first step, ubiquitin is activated by a ubiquitin-activating enzyme (E1) in an ATP-dependent reaction. In the second step, the activated ubiquitin is transferred to a ubiquitin-conjugating enzyme (E2 or UBC), forming an E2-Ub thioester. Finally, in the presence of a ubiquitin-protein ligase (E3), ubiquitin is attached to a target protein through an isopeptide bond between the C terminus of ubiquitin and the ε-amino group of a lysine residue in the target protein.
Ubiquitin contains seven lysine residues that can be attached to other ubiquitins in a highly processive reaction to form a polyubiquitin chain. Typically, a polyubiquitin chain that targets a protein for degradation by the proteasome is linked through Lys 48 of ubiquitin 19 . However, ubiquitin chains that are linked through other lysines of ubiquitin have also been found in cells 20 . In particular, polyubiquitin chains linked by Lys 63 R E V I E W R E V I E W P E R S P E C T I V E R E V I E W FOCUS ON THE UBIQUITIN-PROTEASOME SYSTEM have recently been found to regulate DNA repair and protein-kinase activation through a degradation-independent mechanism (see below). Ubiquitination of IκΒ is carried out by an E2 of the UBC4/5 family 7, 9, 21 and the SCF-βTrCP E3 ligase (SKP1-CUL1-F-box ligase containing the F-box protein βTrCP) [22] [23] [24] [25] [26] . Two βTrCP proteins, βTrCP1 and βTrCP2, have been found in mammalian cells. Genetic deletion of βTrCP1 in mice leads to only modest retardation of IκΒα degradation, suggesting that βTrCP1 and βTrCP2 may have redundant functions 27 . Indeed, silencing of both βTrCP1 and βTrCP2 expression by RNA-mediated interference (RNAi) blocks IκΒα degradation. βTrCP1 and βTrCP2 bind specifically to the phosphorylated form of IκΒ through their Cterminal WD40 repeats, and to the rest of the SCF complex through the F-box. The SCF complex contains the RING-domain protein ROC1/ RBX1, which binds to UBC4/5, allowing this E2 to ubiquitinate IκB at two conserved N-terminal lysine residues. The polyubiquitinated IκΒ remains associated with NF-κΒ, but is selectively degraded by the 26S proteasome, while NF-κΒ itself is spared 7 . The ubiquitin-proteasome pathway is also responsible for the processing of p105 and p100 to p50 and p52, respectively. p105 can be processed either co-translationally or post-translationally; both processes require the proteasome 6, 28 . Co-translational processing of p105 seems to be a constitutive process that does not require phosphorylation or ubiquitination and is probably the major source of p50, which is constitutively present in unstimulated cells. Some agents, such as phorbol ester (PMA) and lipopolysaccharide (LPS), can stimulate post-translational processing of p105 by activating IKK, which phosphorylates p105 at a C-terminal domain 29 . On the other hand, the processing of p100 is tightly regulated by the non-canonical pathway of NF-κΒ activation and depends on both phosphorylation and ubiquitination. As discussed above, stimulation of certain receptors of the TNFR family on B cells activates IKKα, which phosphorylates p100 at two C-terminal serine residues (Fig. 1) . This phosphorylation relieves the inhibition of p100 processing by a C-terminal death domain, and recruits the SCF-βTrCP ligase to polyubiquitinate p100 at a specific lysine 16, 17, 30, 31 . Subsequently, the C-terminal IκB-like domain is selectively degraded by the proteasome, generating the mature p52 subunit.
How does the proteasome partially degrade a protein? More specifically, what defines where degradation starts and where it stops? A plausible model for regulated ubiquitin/proteasome-dependent processing has recently been proposed 32 . According to this model (Fig. 2) , the ubiquitin tag on a substrate recruits the proteasome to an internal unstructured sequence, such as the glycine-rich region (GRR) of p105 and p100 (ref. 33) . It is postulated that this region forms a hairpin-like loop that inserts into the proteolytic chamber of the 20S proteasome. Proteolysis begins at the loop and then proceeds in both the N-and C-terminal directions of the target protein. In most cases, the N-and C-terminal domains can be completely unfolded by the 19S subcomplex of the proteasome and threaded into the proteolytic chamber so that the target is completely degraded. In the case of substrates such as p105 and p100, the RHD domain is a tightly folded structure that may be difficult to unfold. Therefore, after initiating proteolysis from the putative GRR loop of p105 or p100, the proteasome chews along the C-terminal polypeptide until it reaches the end, but comes to a halt at the N terminus when it encounters the tightly folded RHD structure.
The non-traditional role of ubiquitin in activating protein kinases Serendipity played a major part in the discovery of a ubiquitinationdependent IκB kinase complex 9 . In 1995, a cell-free system was established to demonstrate the signal-induced ubiquitination of IκΒα 7 . This system was later used to identify the enzymes involved in IκΒ ubiquitination by separating HeLa cytosolic extracts into two fractions -dubbed fractions I and II (refs 1, 9). Surprisingly, each fraction alone no longer The NF-κB signalling pathways. In the canonical pathway (left), stimulation of TNF receptors (TNFRs), the IL-1 receptor (IL-1R) or Toll-like receptors (TLRs) with their cognate ligands activates TNFR-associated factor (TRAF) proteins and subsequently TGFβ-activated kinase 1 (TAK1), which phosphorylates and activates IKKβ. IKKβ then phosphorylates IκB, resulting in its ubiquitination by the SCF-βTrCP ubiquitin-ligase complex and subsequent degradation by the proteasome. The NF-κB (nuclear factor kappa enhancer binding protein) dimer, which consists of p50 and REL-A, can then enter the nucleus to regulate the expression of targets genes that are involved in inflammation, immunity and cell survival. In the non-canonical pathway (right), a subset of receptors belonging to the TNFR superfamily, such as the B-cell receptor for BAFF (BAFF-R), activates the kinase NIK through an unknown mechanism. NIK then phosphorylates IKKα, which in turn phosphorylates the NF-κB precursor p100. p100 is subsequently polyubiquitinated and then processed to the mature subunit p52 by the proteasome. p52 and its binding partner REL-B translocate to the nucleus to turn on genes that are important for the maturation of B cells.
supported IκΒα phosphorylation. However, when both were combined, or when fraction I was replaced with ubiquitin and UBC4 or UBC5, IκΒα phosphorylation was restored. Further purification of fraction II led to the identification of a large kinase complex (relative molecular mass 700,000), the activity of which can be regulated by polyubiquitination in a degradation-independent manner 9 . An important issue concerning the early work on IKK activation by ubiquitin was the lack of a connection between ubiquitination and signalling pathways that were known to activate IKK. This issue was largely resolved by the discovery that TRAF (TNFR-associated factor) proteins are ubiquitin E3 ligases 10 . TRAF proteins have a pivotal role in signalling pathways that are involved in the activation of NF-κB by many cell-surface receptors, including the TNFR superfamily, the IL-1 receptor (IL-1R) and Toll-like receptors (TLRs) 34 . Seven members of this family have been identified in the human genome. With the exception of TRAF1, all TRAF proteins contain an N-terminal RING domain, followed by several zinc-finger domains. Of all the TRAF proteins, TRAF2 and TRAF6 have been the most intensively studied. TRAF2 is recruited to the TNFR complex through binding to the adaptor protein TRADD (TNFR-associated via death domain) 35 . Both TRADD and TRAF2 also interact with the receptor-interacting protein (RIP), a protein kinase that signals in the TNF pathway through a kinase-independent mechanism. TRAF6 is essential for IKK and Jun N-terminal kinase (JNK) activation in the IL-1 and TLR pathways 36, 37 . In these pathways, stimulation of the receptors leads to the recruitment of MyD88, an adaptor protein that further recruits the protein kinases IRAK4 and IRAK1. IRAK1 then binds to TRAF6, which subsequently activates downstream signalling cascades, including those of IKK and JNK.
IKK activation by the TRAF6 and TRAF2 ubiquitin ligases
In a series of biochemical experiments aimed at elucidating the mechanism of IKK activation by TRAF6, two TRAF6-regulated IKK activators (TRIKAs) were identified 10, 11 . TRIKA1 is an E2 enzyme complex that consists of UBC13 and a UBC-like protein, UEV1A 10, 38 . (Fig. 3) . Following ligand binding to IL-1R or TLRs, TRAF6 is recruited to the receptor complexes and forms oligomers. TRAF6 oligomerization activates its ligase activity, leading to Lys 63 polyubiquitination of target proteins including TRAF6 itself. Ubiquitinated TRAF6 recruits TAB2 and activates the TAB2-associated TAK1 kinase, which then phosphorylates and activates IKK. Ubiquitin-activated TAK1 also phosphorylates and activates MKK kinases (such as MKK6), which in turn activate the JNK and p38 kinase pathway 11 . Therefore, TRAF6-mediated polyubiquitination initiates protein-kinase cascades through a degradation-independent mechanism. Recent structural studies have shown that ubiquitin chains that are linked by Lys 48 and Lys 63 adopt different configurations, potentially providing the molecular basis for the distinct signalling functions of these polyubiquitin chains 41 . Like TRAF6, TRAF2 is also a RING-domain ubiquitin ligase (Fig. 4) 40, [42] [43] [44] . A dominant-negative mutant of UBC13 has been shown to block NF-κΒ activation by TRAF2 or TNFα 10 . Overexpression of TRAF2 leads to its polyubiquitination by UBC13/UEV1A, and TRAF2 ubiquitination seems to be important for the activation of JNK 42 . A recent study showed that TRAF2 ubiquitination is essential for JNK, but not p38 or NF-κΒ activation by TNFα 44 . This is probably due to the redundant role of TRAF2 and TRAF5 in NF-κB activation by TNFα, as TRAF2-deficient cells are defective in JNK but not NF-κΒ activation 45 , whereas TRAF2/TRAF5 double-knockout cells are defective in both JNK and NF-κΒ activation 46 . TRAF2 and/or TRAF5 may also ubiquitinate RIP, which is essential for NF-κΒ activation 40, 47 . It has been shown that TNFα induces RIP polyubiquitination, and that ubiquitinated RIP associates with the TNFR as well as with TAB2 (refs 40, 48, 49) . Therefore, it is possible that polyubiquitination of RIP recruits the TAK1-TAB2 complex, which subsequently activates IKK. However, definitive proof that RIP polyubiquitination is required for TNFα signalling is still lacking.
Roles of the TAK1 kinase complex in IKK and JNK activation
As Tak1-knockout mice are early embryonic lethal, it has not been possible to determine whether or not this kinase is essential for NF-κB activation in mice 50 . However, multiple lines of evidence support a crucial role for the TAK1 complex in IKK and JNK activation. First, TAK1 phosphorylates IKΚβ and MKK6 at key serine residues within the activation loop, leading to their activation 11 . Second, silencing of Tak1 expression by RNA interference or inhibition with a specific kinase inhibitor in mammalian cells markedly reduced IKK activation and completely blocked JNK activation by IL-1β and TNFα 40,51,52 . Figure 2 A model for the processing of p100 by the proteasome. Polyubiquitinated p100 is recruited to the proteasome, allowing the flexible glycine-rich region (GRR) to insert into the proteasome as a loop. Degradation of the polypeptide proceeds in both the amino-and carboxyterminal directions. The degradation of the C terminus proceeds to the end, whereas the degradation along the N terminus stops when the tightly folded REL-homology domain (RHD) cannot be unfolded to allow insertion into the proteasome. The resulting p52 subunit and its dimeric partner REL-B is then released from the proteasome.
R E V I E W R E V I E W P E R S P E C T I V E R E V I E W FOCUS ON THE UBIQUITIN-PROTEASOME SYSTEM
Third, mutations of TAK1 in Drosophila melanogaster, or silencing of TAK1 in a D. melanogaster cell line, blocked IKK and JNK in response to bacterial challenge [53] [54] [55] . Therefore, independent genetic and biochemical studies have indicated that TAK1 is important for IKK and JNK activation in both invertebrates and vertebrates. With regards to the role of TAB2 in the NF-κB pathway, a recent study showed that a TAB2-deficient cell line has normal NF-κB activation in response to IL-1β 56 . However, this is probably due to the redundant functions of TAB2 and its closely related homologue TAB3, as RNAi against TAB2 and TAB3 in mammalian cells abrogated IKK activation by IL-1β and TNFα. Moreover, mutations in the D. melanogaster homologue of TAB2 led to severe defects in antibacterial responses (D. Ferrandon, personal communication). Interestingly, most of these mutations have been mapped to the ubiquitin-binding domain of dTAB2, indicating that ubiquitin-mediated activation of TAK1 and IKK is an evolutionarily conserved mechanism. The TAK1 kinase complex also contains TAB1; however, the role of TAB1 in the NF-κB pathway is not clear, as reconstitution experiments showed that TAB1 is dispensable for IKK activation in vitro 11 . In addition, there is no evidence that RNAi or genetic ablation of TAB1 impairs IKK activation 57 . Furthermore, there is no apparent homologue of TAB1 in the D. melanogaster genome. Therefore, it is likely that TAB1 is not involved in NF-κΒ activation, but in the regulation of other pathways, such as the WNT or TGFβ pathway 58, 59 . In fact, TAK1 and TAB1 were first shown to be involved in the TGFβ pathway, but their mechanism of activation in this pathway is poorly understood 60 . Although TAK1 and TAB2 have important roles in innate immune responses in D. melanogaster, the phenotypes of dTAK1 and dTAB2 mutants are not as severe as those of dIKK mutants 53 . Similarly, although RNAi against TAK1, TAB2 and TAB3 severely impaired IKK activation, there is still residual IKK activity (approximately 20-30%). Some of this residual activity may be because depletion by RNAi is incomplete, but it is also likely that there is another minor pathway contributing to IKK activation. One possible activator of IKK is p62, a ubiquitin-associated (UBA) domain protein that binds to TRAF6 and RIP [61] [62] [63] . Mice lacking p62 are partially defective in prolonged NF-κΒ activation by RANK, a TNFR that activates IKK through TRAF6 in osteoclasts 64 . Interestingly, p62 forms a complex with an atypical PKC (ζPKC), representing another potential example of a ubiquitinreceptor-containing kinase complex that is similar to the TAB2-TAK1 complex. Another potential activator of IKK is MEKK3, as murine cells lacking MEKK3 are partially defective in NF-κΒ activation in response to certain stimuli 65, 66 . It is also possible that residual IKK activation does not require an upstream kinase, but is induced by the oligomerization of IKK itself. In this case, TRAF6 (or TRAF2) and RIP may somehow interact with IKK/NEMO to induce its oligomerization, causing IKK to autophosphorylate itself, resulting in its activation.
Ubiquitin signalling in adaptive immunity
Recent studies have revealed that ubiquitin signalling is important in adaptive immunity, particularly in T-cell activation (Fig. 4) . Stimulation of T-cell receptors (TCRs) activates a tyrosine kinase cascade that subsequently activates the serine/threonine kinase PKCθ. PKCθ then induces the formation of a protein complex that is composed of CARMA1, BCL10 and MALT1, all of which are recruited to the lipid rafts where TCRs reside 67, 68 . Two studies have shown that BCL10 and MALT1 induce the Lys 63-linked polyubiquitination of NEMO by UBC13/UEV1A, leading to IKK activation 69, 70 . However, these studies show a discrepancy concerning the E3 ubiquitin ligase for NEMO. In one study, MALT1 directly ubiquitinates NEMO at Lys 399, despite the fact that MALT1 does not contain any known E3 domain 69 . In the other study, MALT1 was found to recruit TRAF6 via its TRAF6-binding sites, and TRAF6, in turn, ubiquitinates NEMO 70 . The latter study showed that MALT1 also induces auto-ubiquitination of TRAF6, which then recruits the TAK1-TAB2 complex to activate IKK. This entire process, from MALT1-mediated polyubiquitination to IκΒ phosphorylation, was reconstituted in vitro using purified recombinant proteins 70 . TRAF6 and TRAF2 are redundant in the TCR pathway, as RNAi of both TRAF2 and TRAF6 effectively blocked IKK activation and IL-2 production by TCR stimulation, whereas RNAi of either TRAF alone was less effective 70 . However, it remains to be seen whether TRAF2 and TRAF6 are required for T-cell activation in vivo.
Emerging evidence for the regulatory role of ubiquitin in diverse signalling pathways NF-κB is regulated by a large variety of stimuli, including microbial pathogens and DNA-damaging agents, which have recently been shown to activate IKK through a ubiquitin-dependent but degradation-independent mechanism. An elegant example was provided in a study of DNA-damage-induced IKK activation 71 . DNA-damaging agents, especially those that generate double-strand breaks, such as topoisomerase inhibitors and gamma irradiation, can activate NF-κΒ in certain cancer cells. This DNA-damage response, which requires the cytoplasmic IKK complex, may be responsible for the resistance of some cancer cells to chemotherapy. A mechanism by which the nuclear DNA-damage signal is transduced to the cytoplasmic IKK complex has recently been uncovered (Fig. 4) 71 . Following DNA damage, a small fraction of nuclear NEMO is modified by the ubiquitin-like protein SUMO, which further retains NEMO in the nucleus. DNA damage also activates the kinase ATM, which phosphorylates NEMO. This phosphorylation leads to the replacement of SUMO by ubiquitin at two lysine residues (Lys 277 and Lys 309) within NEMO. Ubiquitinated NEMO subsequently enters the cytoplasm, where it associates with the rest of the IKK complex, resulting in IKK activation.
Another recent study has provided evidence that Lys 63 polyubiquitination may be involved in IKK activation by NOD1 and NOD2, two cytosolic receptors for intracellular bacteria 72 . Mutations in NOD2 have been closely linked to Crohn's disease, an inflammatory bowel disease. Stimulation of TLR7/8 and TLR9 by viral RNA and CpG DNA, respectively, leads to the activation of both NF-κB and interferon regulatory factor 7 (IRF7), which coordinately regulate interferon production. IRF7 binds to MyD88, which is associated with the endosomal TLRs as well as IRAK and TRAF6. TRAF6 polyubiquitination is required for the activation of IRF7, presumably by promoting the phosphorylation and subsequent nuclear translocation of IRF7.
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FOCUS ON THE UBIQUITIN-PROTEASOME SYSTEM NOD1 and NOD2 activate IKK through RIP2, a RIP1-like kinase. Through a process that is still not well understood, NOD2 and RIP2 induce the attachment of a polyubiquitination chain at Lys 285 of NEMO, thereby activating IKK (Fig. 4) 
73
. Transfection experiments using ubiquitin mutants suggest that the polyubiquitin chain itself is linked through Lys 63 of ubiquitin. Interestingly, the NOD2 mutations that are found in patients with Crohn's disease impair the ability of NOD2 to activate NF-κΒ and to induce NEMO polyubiquitination in cell culture experiments 73 . However, mouse knock-in experiments show that the Nod2 mutations that are associated with the disease lead to NF-κΒ activation rather than inhibition 74 . Therefore, the signalling mechanisms of NOD proteins and the potential role of ubiquitination in NOD signalling require further investigation.
The regulatory role of ubiquitin may not be limited to the NF-κB pathway. Indeed, TRAF6 ubiquitination has recently been found to be important for activation of the transcription factor interferon regulatory factor 7 (IRF7; ref. 75) . IRF7 regulates the production of type-I interferons in response to stimulation of certain TLRs (TLR7, 8 and 9) by viral RNA or bacterial DNA. IRF7 is activated through its phosphorylation by an unknown kinase, which is in turn activated by the MyD88-IRAK4-TRAF6 complex (Fig. 4) . Recent studies have shown that MyD88 and TRAF6 bind to IRF7, inducing its phosphorylation and nuclear translocation. Interestingly, UBC13 and TRAF6 ubiquitination are required for IRF7 activation 75 , suggesting that Lys 63 polyubiquitination of as yet unidentified targets may be involved in the activation of an IRF7 kinase.
Regulation of IKK activation by deubiquitination
Like phosphorylation, ubiquitination is a reversible covalent modification. Two deubiquitinating enzymes (DUBs) have recently been shown to be important in suppressing NF-κΒ activation at a step upstream of IKK. One of these DUBs is the cylindromatosis tumour suppressor protein CYLD, which inhibits IKK activation by cleaving Lys 63-linked polyubiquitin chains on several proteins, including TRAF2, TRAF6 and NEMO [76] [77] [78] . Mutations within the DUB domains of CYLD, which are found in patients with cylindromas, lead to the enhanced activation of NF-κΒ, thereby contributing to the pathogenesis of the tumours. A recent study found that CYLD also inhibits JNK activation 79 , which is consistent with the idea that CYLD interferes with TRAF ubiquitination or TAK1 activation, which functions upstream of both IKK and JNK. However, this study found that CYLD inhibits IKK activation by IL-1β, LPS and CD40, but not TNFα, whereas previous studies showed that CYLD inhibits IKK activation by TNFα [76] [77] [78] . The reason for this discrepancy is not clear. Another DUB that acts in this pathway is A20, an NF-κΒ-induced protein that inhibits NF-κΒ in a negative-feedback loop [80] [81] [82] . A20-deficient mice develop severe inflammatory diseases in multiple organs, partly due to the enhanced and prolonged activation of NF-κΒ by proinflammatory stimuli, including TNFα and LPS 83 . A20 contains a novel ovarian tumour (OTU)-type DUB domain at the N terminus, and several zinc-finger domains in the remainder of the protein. The OTU domain disassembles Lys 63-linked polyubiquitin chains from RIP (in the TNFα pathway) 81 and TRAF6 (in the LPS pathway) 80 , thereby suppressing IKK activation. Moreover, A20 also functions as a ubiquitin ligase through its zinc-finger domains to assemble Lys 48-linked polyubiquitin chains on RIP after the Lys 63 chains are removed by the OTU domain 81 . Lys 48 polyubiquitination targets RIP for degradation by the proteasome, further diminishing IKK activation. Therefore, A20 provides a striking example of how switching polyubiquitin chains of different configurations can profoundly influence the signalling and degradation of targets. A20 also inhibits the activation of the transcription factor IRF3 by RNA viruses 84 . In this case, the role of ubiquitin is less clear, as overexpression of an A20 mutant lacking the OTU domain still inhibits IRF3. It seems that A20 binds directly to and inhibits TBK1, an IKK-like kinase that phosphorylates IRF3.
Conclusions and perspectives
The past decade has witnessed tremendous progress in elucidating the intertwining between ubiquitination and phosphorylation in the NF-κΒ pathway. It is now well established that phosphorylation is a prerequisite for the ubiquitination of IκΒ and the NF-κΒ precursors p100 and p105. The identification of the ubiquitination machinery, especially the ubiquitin-ligase complex that contains βTrCP (which binds specifically to phosphorylated substrates), provides the molecular basis for the signal-dependent degradation of IκΒ and processing of p100 and p105. Recent studies have also identified several ubiquitin-pathway components that function upstream of IKK -including the TRAF proteins as E3s; UBC13/UEV1A as E2s; TAB2 and TAB3 as ubiquitin receptors; and CYLD and A20 as DUBs (see Supplementary Information, Table 1 ). These results lend strong support to the hypothesis that ubiquitination can also regulate phosphorylation by activating IKK through a proteasome-independent mechanism.
Although the traditional role of ubiquitin in degrading and processing NF-κΒ inhibitors is widely accepted, there are several important issues that remain to be addressed. For example, what is the mechanism underlying the highly processive polymerization of ubiquitin to form polyubiquitin chains? How are different E2s selected to a common SCF ubiquitin ligase scaffold to ubiquitinate distinct substrates? Is the assembly of a specific SCF complex regulated by the availability of substrates? How is ubiquitinated IκΒ, but not NF-κΒ, that is present within the same complex, selectively degraded by the proteasome? How do p100 and p105 escape complete degradation by the proteasome? Are there additional proteins that escort the ubiquitinated IκΒ or p105/p100 to the proteasome?
Much also remains to be learned about the non-traditional role of ubiquitin in the NF-κΒ pathway. Specifically, how does binding of a ubiquitinated protein (for example, TRAF6 or RIP) to a ubiquitin receptor ( for example, TAB2 or TAB3) activate the receptor-associated kinase (for example, TAK1)? What is the function of NEMO ubiquitination? Does NIK activation in the non-canonical pathway of NF-κΒ activation involve TRAF proteins and/or ubiquitin? Are there other NF-κΒ activation pathways that use ubiquitin as a signalling molecule for IKK activation? Are there other E2s (for example, UBC4/5) and E3s that may regulate IKK? In more general terms, is ubiquitin signalling involved in activating other enzymes, including other kinases and ATPases? In this regard, the 19S proteasome contains multiple ATPases and ubiquitin-binding proteins. Does the binding of polyubiquitinated protein substrates to the 19S proteasome activate its associated ATPase activity? If so, ubiquitin regulation of enzymes may be a unified mechanism underlying both the traditional and non-traditional functions of this protein tag.
